Code Biotherapeutics
Hatfield, US · Founded 2020 · 24 employees on LinkedIn · 8 known investors
Find your way into Code Biotherapeutics
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.
Founders & leadership
LK
Lauren KaskielinChief Business Officer2021–2024Lauren Kaskiel is Executive Officer at Code Biotherapeutics, which develops a non-viral DNA delivery platform for genetic medicines. She brings 20+ years of experience in pharmaceutical and biotech business development, financing, and pipeline strategy.
RC
Robert C. GettsNamed on SEC filing
BM
Brian McVeighinChairman, Chief Executive Officer, and Co-FounderVenture Partner, USA at 4BIO Capital
Board
DK
Dmitry KuzminBoard director
VS
Victor StoneBoard director
EM
Edward MathersBoard director
RL
Robert LinBoard director
RF
Russ FeinBoard director
JT
KR
Kathy RouanBoard director
Investors · 8
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
4BIO Capitalreported · 2 sourcesLondon
Amgen Venturesreported · 2 sourcesThousand Oaks · $1M – $3M
Hatteras Venture Partnersreported · 3 sourcesResearch Triangle · $500K – $4M
JDRF T1D FundreportedBoston
Northpond Venturesreported · 2 sourcesBethesda · $100K – $5M
Takeda VenturesreportedCambridge · $1M – $5M
UCB Venturesreported · 2 sourcesBrussels
Reported raises · per SEC filings
Form D private placements$47.5M disclosed across 2 rounds · 2021–2022
▶$37.5MraisedJun 2022 · 10 investors · Other Health CareRule 506(b)
▶$37.5MraisedJun 2022 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph TruittDirector
- Victor StoneDirector
- Brian McVeighExecutive Officer, Director
- Edward MathersDirector
- Kathy RouanDirector
- Robert C GettsExecutive Officer
- Robert LinDirector
- Dmitry KuzminDirector
- Russ FeinExecutive Officer, Director
- Lauren KaskielExecutive Officer
- Erin BrubakerExecutive Officer
- Offering amount
- $75M
- Amount sold
- $37.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10MraisedApr 2021 · 6 investors · Other Health CareRule 506(b)
▶$10MraisedApr 2021 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Dmitry KuzminDirector
- Victor StoneDirector
- Lauren KaskielExecutive Officer
- Robert C. GettsExecutive Officer
- Joseph TruittDirector
- Edward MathersDirector
- Brian McVeighExecutive Officer, Director
- Kathy RouanDirector
- Robert LinDirector
- Russ FeinDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Code Biotherapeutics do?
- Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.
- Who are Code Biotherapeutics's investors?
- Code Biotherapeutics's investors include New Enterprise Associates (NEA), 4BIO Capital, Amgen Ventures, Hatteras Venture Partners, JDRF T1D Fund, Northpond Ventures, Takeda Ventures, UCB Ventures.
- How much funding has Code Biotherapeutics raised?
- Code Biotherapeutics has disclosed $47.5M raised across 2 rounds.
- Where is Code Biotherapeutics headquartered?
- Code Biotherapeutics is headquartered in Hatfield, US.